A prognostic test to guide adjuvant chemotherapy (ACT) decisions in early-stage non-small cell lung cancer (NSCLC): A cost-effectiveness analysis.

被引：0
|
作者：
Stenehjem, David D.
Bellows, Brandon Kyle
Kaldate, Rajesh R.
Jones, Joshua Timothy
Siebert, Uwe
Brixner, Diana I.
机构：
[1] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[2] Univ Utah, Pharmacotherapy Outcomes Res Ctr, Salt Lake City, UT USA
[3] Myriad Genet Labs Inc, Salt Lake City, UT USA
[4] Myriad Genet Inc, Salt Lake City, UT USA
[5] Univ Hlth Sci Med Informat & Technol, Hall In Tirol, Austria
[6] Univ Utah, LS Skaggs Pharm Inst, Salt Lake City, UT USA
[7] Univ Utah, Program Personalized Hlth Care, Salt Lake City, UT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.e18509
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18509
引用
收藏
页数：1
相关论文
共 50 条
  • [31] PATIENTS' PREFERENCES FOR ADJUVANT CHEMOTHERAPY (ACT) IN EARLY NON-SMALL CELL LUNG CANCER (NSCLC): WHAT MAKES IT WORTHWHILE?
    Mclachlan, Sue-Anne
    Hughes, Brett
    Crombie, Catherine
    Christmas, Tim
    Hudson, Malcolm
    Brown, Chris
    Veillard, Anne-Sophie
    Muljadi, Nick
    Millward, Michael
    Wright, Gavin
    Flynn, Peter
    Windsor, Morgan
    Stockler, Martin
    Blinman, Prunella
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S625 - S626
  • [32] Prognostic Impact of Histology on Early-Stage Non-small Cell Lung Cancer
    Maeda, Ryo
    Yoshida, Junji
    Ishii, Genichiro
    Hishida, Tomoyuki
    Nishimura, Mitsuyo
    Nagai, Kanji
    CHEST, 2011, 140 (01) : 135 - 145
  • [33] Expression of angiogenic genes: prognostic marker in patients with early-stage non-small cell lung cancer (NSCLC)
    Cabrera, A.
    Lewintre, E. Jantus
    Sirera, R.
    Honguero, A.
    Blasco, A.
    Sanmartin, E.
    Gallach, S.
    Guijarro, R.
    Camps, C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 111 - 111
  • [34] COST-EFFECTIVENESS ANALYSIS OF CRIZOTINIB IN METASTATIC ALK plus NON-SMALL CELL LUNG CANCER (NSCLC)
    Montero, Alberto J.
    Lopes, Gilberto
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1211 - S1212
  • [35] International Cost-Effectiveness Analysis of Durvalumab in Stage III Non-Small Cell Lung Cancer
    Kareff, Samuel A.
    Han, Sunwoo
    Haaland, Benjamin
    Jani, Chinmay J.
    Kohli, Rhea
    Aguiar Jr, Pedro Nazareth
    Huang, Yiqing
    Soo, Ross A.
    Rodriguez-Perez, Angel
    Garcia-Foncillas, Jesus
    Domine, Manuel
    de Lima Lopes, Gilberto
    JAMA NETWORK OPEN, 2024, 7 (05) : E2413938
  • [36] COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN ROMANIA
    Ciuleanu, T. E.
    Dediu, M.
    Minea, L. N.
    Baculea, S.
    Szkultecka-Debek, M.
    VALUE IN HEALTH, 2010, 13 (03) : A38 - A38
  • [37] Adjuvant or neoadjuvant chemotherapy in early-stage non-small cell lung cancer (NSCLC): How would staging affect the patients (pts) treated?
    Van Meerbeeck, J. P.
    Nicholson, M.
    Gilligan, D.
    Groen, H. J.
    Nankivell, M.
    Pugh, C.
    Stephens, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] ALINA: efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK plus non-small cell lung cancer (NSCLC)
    Shah, Rajiv
    Solomon, Benjamin J.
    Ahn, Jin Seok
    Dziadziuszko, Rafal
    Barlesi, Fabrice
    Nishio, Makoto
    Lee, Dae Ho
    Lee, Jong-Seok
    Zhong, Wenzhao
    Horinouchi, Hidehito
    Mao, Weimin
    Hochmair, Maximilian
    de Marinis, Filippo
    Migliorino, Maria Rita
    Bondarenko, Igor
    Lohmann, Tania Ochi
    Xu, Tingting
    Cardona, Andres
    Bordogna, Walter
    Ruf, Thorsten
    Wu, Yi-Long
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 243 - 244
  • [39] ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK plus non-small cell lung cancer (NSCLC)
    Solomon, B. J.
    Ahn, J. S.
    Dziadziuszko, R.
    Barlesi, F.
    Nishio, M.
    Lee, D. H.
    Lee, J. S.
    Zhong, W. Z.
    Horinouchi, H.
    Mao, W.
    Hochmair, M. J.
    De Marinis, F.
    Migliorino, M. R.
    Bondarenko, I.
    Lohmann, T. O.
    Xu, T.
    Gavaldon, A. Cardona
    Bordogna, W.
    Ruf, T.
    Wu, Y. L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1295 - S1296
  • [40] COST-EFFECTIVENESS ANALYSIS OF EGFR MUTATION TEST FOR NON-SMALL CELL LUNG CANCER IN CHINA
    Jin, G.
    Yang, L.
    VALUE IN HEALTH, 2017, 20 (05) : A247 - A247
12345